Trial Profile
PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Acronyms PembroX
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 04 Apr 2021 Planned End Date changed from 31 Dec 2021 to 28 Feb 2022.
- 04 Apr 2021 Planned primary completion date changed from 31 Dec 2021 to 28 Feb 2022.